

Adopting Novel Strategic Considerations for Biosimilar Market - OMICS Group Pharmaceutical Conferences

The 2nd international conference and Exhibition on Biowaivers & Biosimilars would be held from 23-25 September 2013 at Raleigh, North Carolina, USA.

LOS ANGELES, CA, USA, July 26, 2013

/EINPresswire.com/ -- Biosimilars or Biologics are biological medical products made or derived from the active drug substance of a living organism by recombination of DNA or Controlled gene expression methods. . This term is often used to describe the officially approved subsequent versions of innovator biopharmaceutical medicines from different producers following the patent expiry.

Biologics exhibit high molecular complexity and are sensitive to manufacturing process. Since copied biological products perform differently from the originally branded product, they might produce severe health consequences. Countries like USA therefore are accepting only a few subsequent versions of biologics.


Biowaivers

Biowaivers are official waive off for a particular drug from the bioequivalence studies. Generic drugs must enter into commercial market only after they attain clean chit in bioequivalence studies. It is more of a regulatory assessment of therapeutic equivalence of a generic drug with that of the original one. Clinical studies are conducted for the new drug to replace the existing one. Under certain conditions, these studies are waived off and the product is directly adopted.

Standard guidelines have been framed in most of the USA and EU countries as for as the Biowaivers are concerned.

Biosimilars-2013:

[OMICS Group](#) announces the 2nd International Conference and Exhibition on Biowaivers & Biosimilars under the theme 'Addressing Novel Strategic Considerations for Biosimilar Market' would be held from 23-25 September 2013 at Raleigh, North Carolina, USA at a time when the Clinical trials and issues related to generic drugs are under heated discussion. The global scientific meet gathers the cream of researchers and professors in the concerned domain. The three-day event kicks off with the opening session and speeches by esteemed members of the keynote forum. The presentations



and talks are divided into relevant tracks. The prominent sessions and corresponding speakers are:

Eminent Speakers at the event

1. Michael Retsky, Harvard School of Public Health, USA
2. Sinerik Ayrapetyan, International Postgraduate Educational Center, Armenia
3. Jeff Lyons, Absorption Systems, USA
4. Ivo Abraham, Center for Health Outcomes & Pharmacoeconomic Research, USA
5. Arturo Solis Herrera, Center for the Study of Human Photosynthesis, Mexico

Major Tracks for the discussion include

1. Challenges and Regulatory Approach for Biosimilars
2. Emerging Biosimilars in Therapeutics
3. Clinical Studies and Clinicians Prospects for Biosimilars
4. Globalization of Biosimilars
5. Biosimilars Innovator Pharmaceutical Products
6. Analytical Strategies
7. Bioequivalence Assessment
8. BCS & IVIVC Based Biowaivers
9. Plant Produced Biosimilar Products

Biosimilars-2013 will provide an excellent and global opportunity to the scientists, partners and pharma leaders from Biopharmaceutical and Biotechnology industries to innovate and to explore the strategic market for [Biosimilars and Biowaivers](#).

For more details on Biosimilars-2013 conference, please visit:

<http://www.omicsgroup.com/conferences/biowaivers-biosimilars-2013/>

For further details contact

Badoni Victor

Biosimilars-2013 Organizing Committee

[Pharmaceutical Conferences](#)

5716 Corsa Ave, Suite110

Westlake, Los Angeles

CA-91362-7354, USA

Office +1- 650-268-9744

Toll No +1-800-216-6499 (USA & Canada)

Email: biosimilars2013@omicsonline.net

Badoni Victor

OMICS Group Incorporation

+1- 650-268-9744

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.